Trials / Completed
CompletedNCT03839524
A Trial Evaluating TG4050 in Ovarian Carcinoma.
A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Transgene · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG4050 | Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks. |
Timeline
- Start date
- 2019-12-09
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
- First posted
- 2019-02-15
- Last updated
- 2025-11-14
- Results posted
- 2025-11-14
Locations
6 sites across 2 countries: United States, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03839524. Inclusion in this directory is not an endorsement.